Lundbeck Blames EU Patent Enforcement Regimes For Generic Drug Agreements
This article was originally published in The Pink Sheet Daily
Executive Summary
The European Commission decides to fine Lundbeck and a number of generic drug manufacturers for conspiring to delay the entry of generic citalopram onto the market, but the final outcome of the case could not be decided for several years.
You may also be interested in...
Servier’s EU Nightmare Continues As Commission Moves To Shut Down Disputed IP Practices
The European Commission’s allegations against Servier for alleged patent abuses could help to clarify the law in this area for original product manufacturers in the long term.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.